članak: 1 od 1  
Archive of Oncology
2004, vol. 12, br. 3, str. 148-151
jezik rada: engleski
izvorni naučni članak
doi:10.2298/AOO0403148Z
Correlation between prostate-specific antigen and histopathological difference of prostate carcinoma
(naslov ne postoji na srpskom)
Živković Slađana
Military Hospital, Surgical Diseases Department, Section Urology, Niš

Sažetak

(ne postoji na srpskom)
BACKGROUND: Adenocarcinoma of prostate (ACP) is one of the most frequent tumors in men older than 50. Prostate specific antigen (PSA) is the most reliable serum marker in the diagnostics and following of prostate carcinoma, and Gleason's system of estimation of tumor differentiation, as well as classical estimation of tumor differentiation from 1 to 3, are generally accepted systems of prostate carcinoma evaluation. METHODS: Forty examined individuals with verified ACP and compared values of PSA and tumor differentiation as well as estimated comparability of these two systems are reported. RESULTS: Highly positive correlation between the values of PSA in serum and the degree of tumor differentiation determined by Gleason's system, as well as the low correlation between PSA and histological differentiation estimated using classical system from 1 to 3 were found. CONCLUSION: It could be concluded that Gleason's system for tumor differentiation determination is more superior system of histological grade determination than the other systems.

Ključne reči

prostatic neoplasms; adenocarcinoma; prostate-specific antigen; neoplasm staging; cytodiagnosis; sensistivity and specificity

Reference

CrossRefPubMedKoBSON

Basso, D., Fogar, P., Piva, M.G., Navaglia, F., Mazza, S., Prayer-Galetti, T., Castellucci, E., Pagano, F., Plebani, M. (2000) Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: Which is clinically effective and when?. Urology, 55(5): 710-5

CrossRefPubMedKoBSON1

Bostwick, D.G. (1994) Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. Am J Surg Pathol, 18(8): 796-803

PubMedKoBSON1

Catalona, W.J., Stein, A.J., Fair, W.R. (1982) Grading errors in prostatic needle biopsies: Relation to the accuracy of tumor grade in predicting pelvic lymph node metastases. J Urol, 127(5): 919-22

Epstein, J.A. (1989) Grading of prostatic adenocarcinoma. u: Epstein J.A. (ur.) Prostate biopsy interpretation. Biopsy Interpretation series, New York: Raven Press, str. 129-51

CrossRefPubMedKoBSON

Epstein, J.I., Chan, D.W., Sokoll, L.J., Walsh, P.C., Cox, J.L., Rittenhouse, H., Wolfert, R., Carter, H.B. (1998) Nonpalpable stage T1c prostate cancer: Prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol, 160(6 Pt 2): 2407-11

CrossRefPubMedChemPortKoBSON2

Gleason, D.F. (1992) Histologic grading of prostate cancer: A perspective. Hum Pathol, 23(3): 273-9

PubMedKoBSON

Gleave, M.E., Hsieh, J.T., Wu, H.C., von Eschenbach, A.C., Chung, L.W. (1992) Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res, 52(6): 1598-605

CrossRefPubMedKoBSON

Horninger, W., Reissigl, A., Rogatsch, H., Volgger, H., Studen, M., Klocker, H., Bartsch, G. (2000) Prostate cancer screening in the Tyrol, Austria: Experience and results. Eur J Cancer, 36(10): 1322-35

CrossRefPubMedKoBSON

Karazanashvili, G., Abrahamsson, P. (2003) Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer. J Urol, 169(2): 445-57

CrossRefPubMedKoBSON

Kuriyama, M., Uno, H., Watanabe, H., Yamanaka, H., Saito, Y., Shida, K. (1999) Determination of reference values for total PSA, F/T and PSAD according to prostatic volume in japanese prostate cancer patients with slightly elevated serum PSA levels. Jpn J Clin Oncol, 29(12): 617-22

CrossRefPubMedKoBSON

Lau, W.K., Bergstralh, E.J., Blute, M.L., Slezak, J.M., Zincke, H. (2002) Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: Influence of concomitant pathological variables. J Urol, 167(1): 117-22

CrossRefPubMedChemPortKoBSON4

Oesterling, J.E., Jacobsen, S.J., Chute, C.G., Guess, H.A., Girman, C.J., Panser, L.A., Lieber, M.M. (1993) Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA, 270(7): 860-4

CrossRefPubMedKoBSON

Oesterling, J.E., Jacobsen, S.J., Klee, G.G., Pettersson, K., Piironen, T., Abrahamsson, P.A., Stenman, U.H., Dowell, B., Lovgren, T., Lilja, H. (1995) Free, complexed and total serum prostate specific antigen: The establishment of appropriate reference ranges for their concentrations and ratios. J Urol, 154(3): 1090-5

1

Petersen, R. (1992) Prostate and seminal vesicles. u: Petersen R. (ur.) Urologic Pathology, New York-Philadelphia, itd: Lippincott, str. 586-648

Poel, H.G., Schalken, J.A., Debruyne, F.M.J. (1991) Image analisys and grading of prostate adenocarcinoma. W J Urol, 9, str. 86-94

Radić, S. (2002) Prostate cancer molecular staging: State-of-the-Art in prostate and breast cancer treatment. u: European school of oncology. Advanced course, September, Education boo. 2000.p. 101-4

CrossRefPubMedKoBSON

Roehl, K.A., Antenor, J.A.V., Catalona, W.J. (2002) Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng./ml. range. J Urol, 168(3): 922-5

CrossRefPubMedKoBSON

Schroder, F.H., van der Cruijsen-Koeter, I., de Koning, H.J., Vis, A.N., Hoedemaeker, R.F., Kranse, R. (2000) Prostate cancer detection at low prostate specific antigen. J Urol, 163(3): 806-12

PubMedChemPortKoBSON6

Stamey, T.A., Yang, N., Hay, A.R., McNeal, J.E., Freiha, F.S., Redwine, E. (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med, 317(15): 909-16

PubMedKoBSON

Tchetgen, M.B., Oesterling, J.E. (1995) The role of prostate-specific antigen in the evaluation of benign prostatic hyperplasia. Urol Clin North Am, 22(2): 333-44

CrossRefKoBSON

Thon, F.W., Gadban, M.C., Truss, M., Kuszyk, M., Hartmenn, U., Tomas, U. (1996) Prostate specific antigen density a reliable parameter for the detection of prostate cancer. World J Urol, 14(1), str. 53-8

Veličković, Lj. (2000) Micromorphological, hystochemical and immunohystochemical characteristics of prostate carcinoma and in surrandins premalignant lesions. Niš: Medical Faculty, dissertation

Veličković, Lj., Katić, V., Tasić, D., Kutlešić, Č., Dimov, D., Đorđević, B., i dr. (2001) Prostate specific antigen (PSA) in neoplastic and hyperplastic prostate tissue. Archive of Oncology, 9(1), str. 100-1

CrossRefPubMedKoBSON

Vis, A.N., Hoedemaeker, R.F., Roobol, M., van der Kwast, T.H., Schroder, F.H. (2001) Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml). Prostate, 47(4): 252-61

PubMedKoBSON

Walsh, P.C. (1992) Why make an early diagnosis of prostate cancer. J Urol, 147(3 Pt 2): 853-4

Živković, S. (1998) Comparation of prostate specific antigen and density of prostate specific antigen in patients with benign hyperplasia of prostate and prostate carcinoma. Niš: Medical Faculty, dissertation